BioSpace News Archive

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring Systems, announces that it has significantly expanded Eversense PASS, a Payment Assistance and Simple Savings program designed to enhance affordability and access to the Eversense E3 CGM System.

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced the initiation of a new clinical program to evaluate its lead compound, Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis.

Ascidian Therapeutics announced that Head of Research Robert Bell, Ph.D., will present new data from its lead ABCA4 program at the Twenty-Sixth Annual Meeting of the American Society of Gene and Cell Therapy.

Kernal Bio announced that Yusuf Erkul, M.D., Co-founder & CEO, will present the company’s novel mRNA 2.0 platform at the Locust Walk RNA Innovation Conference on Tuesday, May 9, 2023, at 1:00 p.m. ET.

Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has been named to Inc. magazine’s annual Best Workplaces list.

Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.

Syros Pharmaceuticals announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference.

bluebird bio, Inc. reported financial results and business highlights for the first quarter ended March 31, 2023, including recent commercial and operational progress, and regulatory updates.

Mariana Oncology today announced the appointment of Linda Bain as Chief Operating Officer and Chief Financial Officer.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced financial results for the first quarter ended March 31, 2023.